Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04925193
Title Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Colorado, Denver

multiple myeloma


Carfilzomib + Dexamethasone + Selinexor

Daratumumab + Dexamethasone + Selinexor

Dexamethasone + Pomalidomide + Selinexor

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.